Eli Lilly and Company

(New York Stock Exchange)
Back to all articles
Bullish +55

What Has Changed About Owning Eli Lilly Stock?

Capacity expansion Company update AI-generated analysis

🏭 Eli Lilly spent $19.0 billion on capital projects in the twelve months ended September 30, 2026, surpassing its $15.4 billion research and development spending for the first time since 2011.

πŸ’Š Mounjaro and Zepbound combined generated over $16 billion in revenue during the third quarter, driving the company's aggressive expansion into new manufacturing facilities.

πŸ“ˆ The company broke ground on a $6.5 billion facility in Houston and plans additional sites in Richmond, Virginia, as part of ten new U.S. manufacturing locations announced since 2020.

πŸ’° Free cash flow dropped to $4.16 billion in the third quarter from $6.03 billion a year earlier due to the surge in capital spending on factories and equipment.

πŸ“‰ Net debt increased to $44.6 billion by September 2026, but remains low relative to market value at 3.9%, significantly below the S&P 500 average of 19.1%.

πŸ”­ Investors are urged to watch the capital-to-research spending ratio in upcoming reports, with the next financial update expected on a fourth-quarter call in January.

πŸš€ Over the five years to October 2026, Eli Lilly's stock rose 482%, outperforming 57 of the 60 other pharmaceutical companies in the sector.

Bullish Signals
  • Mounjaro and Zepbound combined generated more than $16 billion in revenue during the third quarter, demonstrating strong demand for its weight-loss and diabetes portfolio.
  • The company's net debt of $44.6 billion represents only 3.9% of its market value, a significantly healthier leverage ratio compared to the S&P 500 average of 19.1%.
  • Full-year free cash flow grew to $11.7 billion for the twelve months ended September 2026, indicating that overall cash generation remains robust despite heavy capital investment.
  • Eli Lilly has announced ten new U.S. manufacturing sites since 2020, signaling a clear and funded long-term growth strategy supported by management confidence.
Risk Factors
  • Capital spending of $19.0 billion exceeded research and development spending of $15.4 billion in the trailing twelve months, ending a streak of 59 quarters where R&D was the larger investment.
  • Free cash flow declined to $4.16 billion in the third quarter from $6.03 billion a year earlier due to the substantial increase in capital expenditures on new factories.
  • Net debt rose to $44.6 billion by September 2026, up from approximately $32.6 billion a year earlier, reflecting the cash outflow required for aggressive capacity expansion.
Full Analysis
Eli Lilly (LLY) has shifted its capital allocation strategy, marking a historic change where capital spending on factories and equipment exceeded research and development for the first time since at least 2011. Over the twelve months ended September 30, 2026, the company spent $19.0 billion on capital projects compared to $15.4 billion on R&D, a reversal after 59 consecutive quarters of higher research investment. This strategic pivot is driven by management's confidence in sustained growth for its weight-loss and diabetes portfolio, specifically Mounjaro and Zepbound, which generated over $16 billion in revenue during the third quarter alone. To support this expansion, Eli Lilly has announced plans for new manufacturing sites, including a $6.5 billion facility in Houston and another in Richmond, Virginia, bringing the total number of new U.S. manufacturing sites since 2020 to ten. Financially, the heavy investment impacted free cash flow dynamics in the third quarter, which fell to $4.16 billion from $6.03 billion a year prior due to increased capital outlays, though full-year free cash flow still grew to $11.7 billion. The company's net debt rose to $44.6 billion by September 2026, yet remains manageable at 3.9% of market value compared to the S&P 500 average of 19.1%, reflecting its strong balance sheet despite the aggressive expansion. Analysts and investors are advised to monitor the ratio of capital spending to research spending in future quarterly reports, with the next update expected on a fourth-quarter call in January. While the shift away from pure R&D dominance raises questions about long-term pipeline depth, the immediate driver is the need to build capacity for blockbuster drugs that have propelled the stock's significant outperformance over the last five years.